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Disclaimer
Objectives
• Discuss  pain in the larger context of suffering
• Identify the differences between nociceptive and 
neuropathic pain
• Review pharmacological treatment strategies for 
nociceptive and neuropathic pain
• Discuss management of rapidly escalating pain
Chronic non-cancer pain is a 
separate entity from EOL pain, with 
different management principles and 
challenges.   






• Care Center/Nursing Home
• Hospital
• Hospice Room in Community Hospital
• Home




Pain Management in Family Medicine
• Know the story
• Match pharmacology to individual need
• Titrate medication to response 
• Communicate effectively
• Understand OME
• Understand opiate incomplete cross-tolerance
• Be able to recognize and reverse opiate toxicity
• Be able to manage a pain crisis
Pain Definition
“…….a somatic perception containing: (1) a 
bodily sensation with qualities like those reported 
during tissue-damaging stimulation, (2) an 
experienced threat associated with this sensation, 
and (3) a feeling of unpleasantness or other 
negative emotion based on this experienced 
threat.“  
Price DD. Psychological Mechanisms of Pain and Analgesia In 



















“Death is not a strictly medical 
event, and many patients’ and 
families’ most pressing needs 
are not medical in nature.”
Panel comments, Dying in America: Improving Quality 
and Honoring Individual preferences Near the End of 
Life, Institute of Medicine. http://www.iom.edu/Reports.  
Released 9/14/14  




• No exact definition
• Multiple trajectories to death
• NIH
“People can, in some respects, be considered to be approaching 
death from the moment they are born.”
National Institutes of Health. National institutes of health state-of-the-science 
conference statement of improving end-of-life care, 
http://consensus.nih.gov/2004/2004EndOfLifeCareSOS024html.htm
• Practical working definition:  life-limiting illness with high 














• Preoccupying (“All I think about”) 7-8
• Excruciating (“Worst ever”) 9-10
Wong-Baker Facial Pain Scale
No Pain Worst Pain Ever
Nociceptive Pain
A nociceptor is a nerve fiber preferentially sensitive to a 
noxious stimulus. 
Nociceptive pain is the perception of nociceptive input, 
usually due to tissue damage. 




• Arises from injury to body tissues
• Well localized but varies in description and experience
• Visceral
• Arises from viscera mediated by stretch receptors
• Poorly localized
• Deep, dull, cramping
Rosenquist E, Aronson M, Park L  Definition and pathogenesis of 
chronic pain.  UpToDate
Neuropathic Pain
• Pain caused by a primary nerve injury or dysfunction in 
the nervous system
• Responsible lesion may be of any type and occur at any 
location along the sensory transmission pathways
• May be directly related to a life-threatening disease or by 
a co-morbidity
• May be constant or fluctuating intensity
• May be paroxysmal 
• May be spontaneous or provoked by stimulus
• Descriptors may help identify pain as neuropathic
Oxford Textbook of Palliative Medicine, Fourth Edition.  Hanks, 







• Pins and needles
• Electric shock
• Cold
Patients often have combination of 
neuropathic and nociceptive pain 
(“mixed pain”).  Effective pain 





• Liver disease 
• Pts on warfarin
• Avoid alcohol with significant scheduled doses





• History of ulcers/GI bleeding
• CHF
• Advanced liver disease
• Concurrent anticoagulants  
Codeine
• Constipating
• Direct anti-tussive effect
• Metabolic Variation
• Converted to MORPHINE via CYP2D6 pathway
• Approximately 7% of Caucasians lack CYP2D6 activity
• Negligible analgesic effect in these patients
• “Ultra-rapid metabolizers” (small subset)
• Potential for extensive conversion to morphine and associated adverse 
effects
• Impact may be greatest in pediatric population
Tramadol
• Weak opioid mu-receptor agonist
• Inhibits uptake of serotonin and norepinephrine
• SNRIs have the same effect
• Fairly rapid pain relief
• Potential to ↓ seizure threshold
• Serotonin syndrome potential
• SNRI
• SSRI
• Start with 50 mg PO every 4 hours
• Maximum dose 400 mg/day
• Renal or hepatic impairment requires dose adjustment
Dworkin R, O’Connor A, Audette J, et al. Recommendations for the 
pharmacological management of neuropathic pain: an overview and 
literature update. Mayo Clinic Proc March 2010; 85(3)(suppl):S3-S14
Hydrocodone
• Hydrocodone + acetaminophen
• Vicodin
• Lortab
• In 2007, 99% of worldwide hydrocodone consumed in US
International Narcotics Control Board Report 2008
• Schedule III  Schedule II August 2014
• Converted via CYP2D6 pathway to HYDROMORPHONE
• Zohydro ER approved by FDA in 2014
• Concerns re: potential for substance abuse
• FDA review panel recommended 12-2 against approval










Fentanyl N/A 100 mcg (single dose)
Opiate Adverse Reactions
• Constipation
• All patients on regular opiates must have a bowel regimen 
prescribed
• Docusate has no proven efficacy








• Ordinarily non-painful stimuli evoke pain
Opiate Principles
• Respiratory depression risk highest in opioid-naïve pts
• Start low and titrate
• Prescribe smaller amounts of short-acting opiate initially
• See patients 1-2 times/wk to adjust dosages until pain is 
consistently in 2-3/10 range
• Avoid mixing opiates when possible
• Morphine SR BID + oxycodone Q 4 hours PRN
• One SR opiate (when appropriate) + one IR
• Goal is pain controlled to patient’s satisfaction 
Initial Opioid Dosing
• Morphine
• 2.5-5 mg PO q. 2-4 hours PRN
• 1 mg IV/SC q. hourly PRN
• Hydromorphone
• 1 mg PO q. 2-4 hours PRN
• 0.1-0.2 mg IV/SC q. 1 hour PRN
• Fentanyl
• 12-25 mcg IV/SC q. 1 hour PRN 
• Hydrocodone/Acetaminophen
• 2.5-5 mg PO of the hydrocodone component
• Hepatic CYP2D6hydromorphone 
Opiates in Renal or Hepatic Dysfunction 
Renal
• Codeine
• Do not use
• Fentanyl
• Generally safe
• May need dose reduction
• Hydromorphone




• Use with caution
• Active metabolites can accumulate
• Oxycodone
• Caution




• Do not use
• Fentanyl
• Generally safe
• No dose adjustment necessary (1 dose)
• Hydromorphone
• Caution
• Reduce dose by 50%
• Methadone
• Do not use long-term 
• May accum in severe hepatic dysfunction
• Morphine
• Use with caution
• Conversion to inactive metabs may not 
happen; increase dosing intervals
• Oxycodone
• Use with caution
• Reduce initial dose 50% and monitor
Groninger H, Vijayan J Pharmacologic 
management of pain at end of life.  Am Fam
Physician 2014 Jul 1;90 (1):26-32
Methadone
• Racemic mixture of d- and l-isomers
• d-isomer is not an opiate but a potent N-methyl-D-aspartate 
antagonist
• Analgesia in neuropathic pain
• Long plasma half-life (can range from 12  to 150 hours)
• Steady state may take up to 4 weeks to achieve
• Doses should not be changed more frequently than weekly 
unless the patient is in a closely monitored setting
• Potential for QTc prolongation
• Watch drug interactions
• EKG in selected patients
• Caution in doses > 100 mg per day
• Should only be used by clinicians familiar with its 
unique properties
Brglio K, Abrahm J, Savarese D  Pain assessment and management in 
the last weeks of life.  UpToDate
Opiate Stewardship Education
• Sharing opioid medication with others may cause them to 
have serious reactions or death
• Selling or giving away opioid medication is illegal




• Wanted and unwanted
• Pets
• Proper disposal of unused medication
• Used fentanyl patch still has enough medication to harm or kill a 
child
Monograph: ER/LA Opioids: Achieving Safe Use While Improving 
Patient Care. August 2014 Collaborative for REMS Education, 
California Academy of Family Physicians
Behaviors Suggestive of Misuse
• Adverse life consequences (e.g., a lost job, relationship 
problems)
• Current abuse of other substances
• Indications of drug seeking behavior (e.g., seeks early 
refills)
• Lack of cooperation with opioid treatment plan (e.g., does 
not follow up with clinical team, refuses to use nonopioid 
therapies)
• Lack of reliability taking drug (e.g., self-titrates drug, runs 
out early)
• Loss of control of drug use (e.g., loses prescriptions)
Groninger H, Vijayan J Pharmacologic management of pain at end 
of life.  Am Fam Physician 2014 Jul 1;90 (1):26-32
Treatment Options for Neuropathic Pain










Haanpaa M, Gourlay G, et al. Treatment considerations for patients 
with neuropathic pain and other medical comorbidities. Mayo Clinic Proc March 
2010; 85(3)(suppl):S15-S25
Tricyclic Antidepressants
• Extensive literature re: efficacy
• Efficacy questionable in HIV and chemo Rx associated neuropathy
• Inexpensive
• Anti-cholinergic adverse effects may be limiting factor
• Secondary amine TCA better tolerated (nortriptyline; desimpramine)
• Start with 10 mg @ HS
• Increase by 10-25 mg every 3-7 days 75-100 mg
• Avoid or use with caution in elderly
• Avoid or use with great caution in pts with cardiac 
conduction disturbances or arrhythmia
• Contraindicated after recent MI
• Discuss with pharmacology consultant if any questions
SNRI’s
• Duloxetine
• Efficacy best shown in diabetic neuropathy
• Evidence for efficacy in chemotherapy induced neuropathy
• Adequate trial is 4 weeks
• Nausea is most common adverse effect
• Start 30 mg daily for 1 week, then increase to 60 mg daily
• No significant BP or cardiovascular effects
• Venlafaxine
• Two to for weeks needed to titrate to effective dose (150-225 mg/day)
• Adequate trial is 4-6 weeks
• Potential to increase BP
• Must taper if treatment discontinued
• Potential for very uncomfortable withdrawal syndrome
Dworkin R, O’Connor A, Audette J, et al. Recommendations for 
the pharmacological management of neuropathic pain: an 
overview and literature update. Mayo Clinic Proc March 2010; 
85(3)(suppl):S3-S14
Topical Lidocaine
• Efficacy of 5% lidocaine patch established in RCTs 
studying different types of NP pain
• Main use is for localized NP
• Helpful for allodynia
• Mild local reactions are main adverse reaction
• No significant systemic reactions or drug interactions
• Lidocaine 5% gel less expensive than patch and has 
demonstrated efficacy
Dworkin R, O’Connor A, Audette J, et al. Recommendations for the 
pharmacological management of neuropathic pain: an overview and 
literature update. Mayo Clinic Proc March 2010; 85(3)(suppl):S3-S14
Gabapentin
• Binds to voltage-gated calcium channels and inhibits 
neurotransmitter release
• Dose dependent dizziness and sedation
• Start at low doses (100 mg @ HS for elderly; otherwise 
100 mg TID) and titrate gradually
• Dosage reduction needed for renal insufficiency
• Dose Limits:
• Pain relief
• Intolerable side effects
• Maximum dose of 3600 mg daily in divided doses
• Angioedema an uncommon but reported adverse reaction
Pregabalin (Lyrica)
• Same mechanism of action as gabapentin
• Approved FDA 12/31/2004 
• Schedule V
• Starting dose is 50 mg TID
• Increase to 300 mg/day after 3-7 days
• Maximum dose is 600 mg/day, but no evidence of added efficacy 
above 300 mg/day
• Dose reduction needed for renal insufficiency
• Angioedema is a potential adverse reaction
• No clear evidence of superiority of pregabalin over 
gabapentin
Treatment Options for Neuropathic Pain
• A combination of gabapentin and an opioid has been 
shown to achieve better analgesia than either drug 
alone
• Gilron I, Bailey J, Tu D, et al. Morphine, gabapentin, or their combination for 
neuropathic pain. NEJM 2005;352(13):1324-1334
• Hanna M, O’Brien C, Wilson MC. Prolonged-release oxycodone enhances the 
effects of existing gabapentin therapy in painful diabetic neuropathy patients. 
Eur J Pain 2008;12(6):804-813
• Combined gabapentin and nortriptyline therapy has 
been shown to be more efficacious than either drug 
given alone for post-herpetic neuralgia
• Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a 
double-blind, randomised controlled crossover trial. Lancet    
2009;374(9697):1252-1261












• Criteria for Use: 
• Depressed mental status: difficult/unable to arouse 
• Shallow respirations or rate less than 8/minute + evidence of inadequate 
ventilation (e.g. low oxygen saturation, hypotension). 
• Stop opioid administration.
• Dilute 0.4 mg naloxone (one amp) with NS to total volume of 10 ml (0.04 mg/mL)
• Prompt pt to breathe deep breaths
• Administer 1 ml IV (0.04 mg) q1min until the patient is responsive. 
• A typical response is noted after 2-4 ml with deeper breathing and greater level 
of arousal. 
• If no response to 0.8 mg (2 amps), consider other causes of sedation and 
respiratory depression
• Repeated doses of naloxone, or even a continuous naloxone infusion, may be 
needed.
• Wait for sustained improvement in consciousness before restarting opioids at a 
lower dose
Dunwoody CJ, Arnold R. Using naloxone. Fast Facts and Concepts #039 End 
of Life/Palliative Education Resource Center
Opioid Dose Escalation
• For ongoing moderate to severe pain increase opioids 
doses by 50-100%, irrespective of starting dose
• For ongoing mild to moderate pain increase by 25-
50%, irrespective of starting dose
• Dosage escalations of less than 25% generally have 
no significant efficacy.
• Short-acting oral single-agent opioids can be safely 
dose escalated every 2 hours (clinician supervised)
• Sustained-release oral opioids can be escalated every 
24 hours.
Fast Facts #020 www.eperc.mcw.edu
Opiate Rotation
• Reduce opioid dose by 30-50% to accommodate for 
unknown cross-tolerance and titrate to goal.
• The wide variation among individuals is multifactorial and 
poorly understood.
• Incomplete cross-tolerance can lead to greater than 
anticipated potency in a new opioid, even though same 
class of analgesic is being used.
• Monitor clinical response and adverse effects.
Kishner S. Opioid equivalents Medscape
PCA
• Uses
• Pain is escalating and not controlled with oral regimen
• Persistent vomiting
• Transition after procedures
• More precise determination of opiate need
• Somnolence occurs before respiratory depression
• Basal infusion can be added once PRN use is assessed
• Typical starting dose in opiate naive pt:
• Hydromorphone 0.1 mg IV with 12 min lockout
• Morphine 1 mg IV with 12 min lockout
• Fentanyl 12 mcg with 12 min lockout
• Patient or nurse activated, NOT FAMILY!
PCA Conversion  
• 64 yo male, with metastatic SCC of lung with metastasis to liver, 
bone, and subcutaneous tissues has been on MS Contin 30 mg PO 
BID + 5 mg oral morphine every 2 hours PRN for breakthrough pain.  
In the last 24 hours he has used 5 doses of oral morphine, and 
presents to ED with vomiting and persistent pain that he rates 8/10.  
He has normal renal function and is alert.  You decide to rotate to 
hydromorphone using a PCA.
• Calculate total OME
• 30 + 30 + (5 x 5) = 85 mg in 24 hour = 3.5 mg per hour
• Convert to equivalent IV HYDROMORPHONE
• 3.5 ÷ 20 = 0.175 mg x 0.7 = 0.123 mg 0.1 mg IV hydromorphone per 
hour 
• PCA dose 0.1 mg hydromorphone with 12 min lockout
• Reassess pain control in 6-8 hours and adjust dose
Pain Crisis Management
• Morphine 2 mg IV initial dose
• If no response in 10 minutes repeat 2 mg dose
• If no response in 10 minutes, give 5 mg Q 10 min x 2 doses
• If no response give 10 mg Q 10 minutes until pain controlled
• Once a dose is starting to relieve pain, continue with that same 
bolus dose every 10 minutes until pain is 2-3/10.
• ONCE PAIN CONTROLLED:  calculate total amount of opiate used
• Give this amount over 24 hours as basal infusion with bolus dose the 
same mg as used for hourly infusion
• Example:
• 2 mg + 2 mg + 5 mg + 5 mg + 10 mg morphine  controls pain
• 24 mg ÷ 24 = 1 mg/hour basal morphine infusion
• PCA (or NCA) bolus 1 mg with 12 min lockout
• If pain starts to escalate, ↑ infusion + bolus by 100% & reassess
IV Lidocaine in Opioid-Resistant Pain
• Randomized, double-blinded, placebo-controlled, cross over 
study of 50 consecutive cancer patients not responding to 
maximally tolerated morphine dose
• Primary end-points:  Magnitude of pain relief and durability of 
response 
• Equal volumes of NS or Lidocaine
• Lidocaine
• 2 mg/kg bolus
• 2 mg/kg infusion over one hour
• ECG monitoring during bolus and for 2 hrs following infusion
• Non-invasive BP and respiratory rate monitoring every 10 min
Sharma S, Rajagopal M, Palat G, Singh C, et al.  A phase II pilot 
study to evaluate use of intravenous lidocaine for opoid-refractory 
pain in cancer patients. Journal of Pain and Symptom Management 
Jan 2009;(37)1:85-93




• 9 (18%) Neuropathic
Sharma S, Rajagopal M, Palat G, Singh C, et al.  A phase II 
pilot study to evaluate use of intravenous lidocaine for opoid-
refractory pain in cancer patients. Journal of Pain and 
Symptom Management Jan 2009;(37)1:85-93
IV Lidocaine in Opioid-Resistant Pain
Lidocaine Placebo
Mean time to 40 min 75 min
maximal effect
Mean duration 9.34 days 3.82 days
of pain relief
% of patients reporting                      64% 30%
subjective decrease
in analgesic requirements
in 14 day f/u observation
period
Sharma S, Rajagopal M, Palat G, Singh C, et al  A phase II 
pilot study to evaluate use of intravenous lidocaine for opoid-
refractory pain in cancer patients. Journal of Pain and 
Symptom Management Jan 2009;(37)1:85-93
Summary 
• Pain has sensory and emotional elements
• Pain in EOL scenarios often has nociceptive and 
neuropathic aspects to consider
• Effective EOL pain management utilizes opiate and non-
opiate medication
• Escalating pain should be anticipated in EOL care
• Escalating pain can be effectively managed by family 
physicians
